Related Experiment Videos
Methylphenidate and growth: demonstration of a growth impairment and a growth-rebound phenomenon
Abstract:
Methylphenidate (MPH), the drug of choice in the treatment of attention deficit disorder with hyperactivity (ADD/H), has been shown to reduce the body stature of some patients. The present study was undertaken to determine if MPH suppresses growth in rats, and whether the clinical observation of a growth rebound phenomenon could be experimentally demonstrated. Our results demonstrate that neonatal rats treated with MPH show a reduction in femur length and a reduction in thyroid, pituitary, testis, adrenal gland, and brain weights immediately following drug cessation. However, a growth-rebound phenomenon occurs such that there are no differences between treated and control groups within 30 days of the last drug exposure. These data, along with those from the clinical literature, suggest that growth impairment is most likely a result of the acute effects of the drug. Further, these data suggest that when administered at therapeutic doses which avoid significant weight loss in the patient, MPH is not likely to cause growth impairment in children.
Insights
Methylphenidate (MPH) may temporarily reduce growth in young rats, but a rebound effect occurs after treatment stops. This suggests MPH is unlikely to cause long-term growth impairment in children at therapeutic doses.
Area of Science:
- Pharmacology and Toxicology
- Developmental Biology
- Endocrinology
Background:
- Methylphenidate (MPH) is a primary treatment for attention deficit disorder with hyperactivity (ADD/H).
- Clinical observations suggest MPH may reduce body stature in some patients.
Purpose of the Study:
- To investigate the effects of MPH on growth suppression in neonatal rats.
- To experimentally determine if a growth rebound phenomenon occurs after MPH cessation.
Main Methods:
- Neonatal rats were treated with Methylphenidate (MPH).
- Femur length and organ weights (thyroid, pituitary, testis, adrenal gland, brain) were measured post-treatment.
- Growth rebound was assessed by comparing treated and control groups after drug cessation.
Main Results:
- MPH treatment resulted in reduced femur length and organ weights immediately after drug cessation.
- A significant growth rebound phenomenon was observed.
- No differences in growth were found between MPH-treated and control rats within 30 days of the last drug exposure.
Conclusions:
- Growth impairment from MPH is likely due to acute drug effects, not long-term suppression.
- The observed growth rebound suggests recovery after MPH cessation.
- Therapeutic doses of MPH, avoiding significant weight loss, are unlikely to cause lasting growth impairment in children.